메뉴 건너뛰기




Volumn 27, Issue 1, 2009, Pages 83-87

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

Author keywords

Intestinal perforations; Pneumatosis; Renal cell carcinoma; Sunitinib treatment

Indexed keywords

INTERLEUKIN 2; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 62749196646     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9146-z     Document Type: Article
Times cited : (34)

References (16)
  • 2
    • 34249894171 scopus 로고    scopus 로고
    • Gastrointestinal perforation due to bevacizumab in colorectal cancer
    • DOI 10.1245/s10434-006-9337-9
    • MW Saif A Elfiky RR Salem 2007 Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann Surg Oncol 14 1860 1869 (Pubitemid 46870935)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.6 , pp. 1860-1869
    • Saif, M.W.1    Elfiky, A.2    Salem, R.R.3
  • 3
    • 33750344419 scopus 로고    scopus 로고
    • Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy
    • 2006 ASCO Annual Meeting Proceedings Part I
    • Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535
    • (2006) J Clin Oncol , vol.24 , pp. 3535
    • Sugrue, M.1    Kozloff, M.2    Hainsworth, J.3    Al, E.4
  • 5
    • 34447121952 scopus 로고    scopus 로고
    • Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
    • DOI 10.1097/JTO.0b013e31805fea51, PII 0124389420070600000017
    • J Gray J Murren A Sharma 2007 Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab J Thorac Oncol 2 571 573 (Pubitemid 47171814)
    • (2007) Journal of Thoracic Oncology , vol.2 , Issue.6 , pp. 571-573
    • Gray, J.1    Murren, J.2    Sharma, A.3    Kelley, S.4    Detterbeck, F.5    Bepler, G.6
  • 8
    • 34648873387 scopus 로고    scopus 로고
    • Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis
    • 2007 ASCO Annual Meeting Proceedings Part I
    • Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010
    • (2007) J Clin Oncol , vol.25 , pp. 5010
    • Gore, M.1    Porta, C.2    Oudard, S.3    Al, E.4
  • 10
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • LB Saltz S Clarke E Diaz-Rubio 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 11
    • 37849035249 scopus 로고    scopus 로고
    • Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortium
    • AA Garcia H Hirte F Fleming 2008 Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium J Clin Oncol 26 76 82
    • (2008) J Clin Oncol , vol.26 , pp. 76-82
    • Garcia, A.A.1    Hirte, H.2    Fleming, F.3
  • 12
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study
    • RA Berger MW Sill BJ Monk 2007 Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 25 5165 5177
    • (2007) J Clin Oncol , vol.25 , pp. 5165-5177
    • Berger, R.A.1    Sill, M.W.2    Monk, B.J.3
  • 13
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • K Miller M Wang J Gralow 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676
    • (2007) N Engl J Med , vol.357 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 16
    • 38149117040 scopus 로고    scopus 로고
    • Pneumatosis intestinalis: A variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity
    • TR Asmis KY Chung JB Teitcher 2007 Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity Invest New Drugs 26 95 96
    • (2007) Invest New Drugs , vol.26 , pp. 95-96
    • Asmis, T.R.1    Chung, K.Y.2    Teitcher, J.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.